Jade Biosciences Inc (JBIO) Stock Price, Quote & News

Company Profile

Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences,...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 312 3013

Website: jadebiosciences.com

Address:

Building 23, Suite 105 221 Crescent Street, Waltham, United States

WallStWireAds Jul. 14 at 4:18 PM

$NVCT https://seekingalpha.com/pr/20582379-streetwatch-nuvectis-pharma-eyes-9_8-billion-oral-pnh-market-with-late-stage-nxp100-backed-by $TGTX $VRTX $JBIO $CRNX

0 · Reply

focafoca99 Jul. 1 at 9:03 PM

$JBIO licensed an exclusive royalty-bearing agreement with Paragon Therapeutics, up to $22 million in milestones.

0 · Reply

focafoca99 Jun. 26 at 11:19 AM

$JBIO appointed Mark Eisner to its board of directors.

0 · Reply

stayput Jun. 24 at 5:01 PM

$JBIO Average $12.57.. sitting pretty

0 · Reply

Irish_lass Jun. 23 at 2:29 PM

$JBIO Thanks XBI

0 · Reply

Irish_lass Jun. 22 at 6:49 PM

$JBIO Swing for the fences

0 · Reply

Irish_lass Jun. 22 at 3:19 PM

$JBIO 👀

0 · Reply

outlawinvestor1 Jun. 19 at 9:59 PM

$APGE 💥🥳 $SYRE $ORKA $JBIO $CBIO https://www.reuters.com/business/healthcare-pharmaceuticals/abbvie-nears-11-billion-deal-apogee-therapeutics-ft-reports-2026-06-19/

0 · Reply

Quantumup Jun. 15 at 12:47 PM

UBS🏁 $JBIO Buy; $45 and said: We believe JBIO's lead program JADE101 could be a best-in-class drug in the $20B+ IgAN market and could have $3-4B in peak sales potential. $VERA $TVTX NVS VRTX IONS AZN Here's what UBS went on to say: https://x.com/Quantumup1/status/2066502213355135474?s=20

0 · Reply

SuperGreenToday Jun. 12 at 10:17 AM

$JBIO Share Price: $16.06 Contract Selected: Nov 20, 2026 $20 Calls Buy Zone: $3.53 – $4.37 Target Zone: $6.24 – $7.63 Potential Upside: 67% ROI Time to Expiration: 160 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors

2026-06-15T09:35:19.000Z - 4 weeks ago

Jade Biosciences initiated with a Buy at UBS

Jun 5, 2026, 4:01 PM EDT - 5 weeks ago

Jade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Jun 5, 2026, 8:00 AM EDT - 5 weeks ago

Jade Biosciences Proxy statement: Proxy filing

2026-06-04T10:37:33.000Z - 5 weeks ago

Jade Biosciences 10M share Secondary priced at $15.00

Jun 3, 2026, 10:58 PM EDT - 5 weeks ago

Jade Biosciences Announces Pricing of Public Offering of Common Stock

2026-06-03T20:05:47.000Z - 5 weeks ago

Jade Biosciences announces common stock offering, no amount given

Jun 3, 2026, 4:01 PM EDT - 5 weeks ago

Jade Biosciences Announces Proposed Underwritten Public Offering

2026-06-02T11:26:23.000Z - 6 weeks ago

Jade Biosciences price target raised to $47 from $32 at Guggenheim

2026-06-01T19:40:08.000Z - 6 weeks ago

Jefferies says Jade Biosciences JADE101 data came in line with bull case

2026-06-01T12:08:46.000Z - 6 weeks ago

Jade Biosciences announces interim results from JADE101 trial

Jun 1, 2026, 8:00 AM EDT - 6 weeks ago

Jade Biosciences Transcript: Study update

Jun 1, 2026, 8:00 AM EDT - 6 weeks ago

Jade Biosciences Slides: Study update

Jun 1, 2026, 8:00 AM EDT - 6 weeks ago

Jade Biosciences Press release: Study update

Jun 1, 2026, 7:00 AM EDT - 6 weeks ago

Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101 Demonstrating Potential Best-in-Class Profile and Every-12-Week Dosing in IgA Nephropathy

Jun 1, 2026, 7:00 AM EDT - 6 weeks ago

Jade Biosciences Slides: Company presentation

May 29, 2026, 4:05 PM EDT - 6 weeks ago

Jade Biosciences to Host Conference Call and Webcast on June 1, 2026, at 8:00 a.m. ET to Discuss Interim Phase 1 Healthy Volunteer Results for JADE101, a Novel, Potentially Best-in-Class Anti-APRIL Monoclonal Antibody in Development for IgA Nephropathy

2026-05-26T20:16:27.000Z - 7 weeks ago

Jade Biosciences announces first participant dosed in JADE201 Phase 1 trial

May 26, 2026, 4:05 PM EDT - 7 weeks ago

Jade Biosciences Announces First Participant Dosed in First-in-Human Phase 1 Clinical Trial of JADE201, a Novel Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody

2026-05-26T11:47:22.000Z - 7 weeks ago

Jade Biosciences announces first participant dosed in Phase 2 Juniper trial

May 26, 2026, 7:00 AM EDT - 7 weeks ago

Jade Biosciences Announces First Participant Dosed in Phase 2 JUNIPER Clinical Trial of JADE101 in IgA Nephropathy

2026-05-11T17:25:16.000Z - 2 months ago

Jade Biosciences price target raised to $34 from $24 at Wedbush

2026-05-11T12:13:00.000Z - 2 months ago

Jade Biosciences price target raised to $32 from $23 at Guggenheim

2026-05-07T22:32:12.000Z - 2 months ago

Jade Biosciences files $600M mixed securities shelf

2026-05-07T22:29:57.000Z - 2 months ago

Jade Biosciences files to sell 39.54M shares of common stock for holders

May 7, 2026, 4:05 PM EDT - 2 months ago

Jade Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 7, 2026, 8:00 AM EDT - 2 months ago

Jade Biosciences Registration statement: Registration filing

May 7, 2026, 8:00 AM EDT - 2 months ago

Jade Biosciences Registration statement: Registration filing

May 7, 2026, 7:00 AM EDT - 2 months ago

Jade Biosciences Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 2 months ago

Jade Biosciences Earnings release: Q1 2026

May 7, 2026, 7:00 AM EDT - 2 months ago

Jade Biosciences Slides: Company presentation

Apr 28, 2026, 8:00 AM EDT - 2 months ago

Jade Biosciences Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 2 months ago

Jade Biosciences Proxy statement: Proxy filing

2026-04-27T10:16:33.000Z - 2 months ago

Jade Biosciences price target raised to $45 from $35 at H.C. Wainwright

Apr 23, 2026, 7:00 AM EDT - 2 months ago

Jade Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

2026-04-22T11:54:28.000Z - 2 months ago

Jade Biosciences appoints Edward Conner as chief medical officer

ARDX

Apr 22, 2026, 7:00 AM EDT - 3 months ago

Jade Biosciences Appoints Edward R. Conner, M.D.

Apr 21, 2026, 11:30 AM EDT - 3 months ago

Jade Biosciences Transcript: 2026 Bloom Burton & Co. Healthcare Investor Conference

Apr 17, 2026, 8:00 AM EDT - 3 months ago

Jade Biosciences Proxy statement: Proxy filing

2026-03-25T10:05:11.000Z - 4 months ago

Jade Biosciences price target raised to $35 from $25 at H.C. Wainwright

2026-03-19T15:30:17.000Z - 4 months ago

Jade Biosciences participates in a conference call with William Blair

2026-03-16T11:57:55.000Z - 4 months ago

Jade Biosciences price target raised to $39 from $28 at BTIG

Mar 11, 2026, 8:40 AM EDT - 4 months ago

Jade Biosciences Transcript: Leerink Global Healthcare Conference 2026

2026-03-11T10:35:11.000Z - 4 months ago

Jade Biosciences price target raised to $23 from $17 at Guggenheim

Mar 6, 2026, 7:00 AM EST - 4 months ago

Jade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Mar 6, 2026, 7:00 AM EST - 4 months ago

Jade Biosciences Annual report: Q4 2025

Mar 6, 2026, 7:00 AM EST - 4 months ago

Jade Biosciences Earnings release: Q4 2025

Mar 5, 2026, 7:00 AM EST - 4 months ago

Jade Biosciences Slides: Corporate presentation

Mar 2, 2026, 10:30 AM EST - 4 months ago

Jade Biosciences Transcript: TD Cowen 46th Annual Health Care Conference

Feb 26, 2026, 1:20 PM EST - 4 months ago

Jade Biosciences Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 11, 2026, 7:00 AM EST - 5 months ago

Jade Biosciences to Participate in Upcoming Conferences

Jan 15, 2026, 2:15 PM EST - 6 months ago

Jade Biosciences Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 7:00 AM EST - 6 months ago

Jade Biosciences Outlines Key 2026 Objectives and Strategy to Advance Pipeline of Potentially Best-in-Class Monoclonal Antibodies Across Multiple Autoimmune Diseases Ahead of the 44th Annual J.P. Morgan Healthcare Conference

Jan 2, 2026, 7:00 AM EST - 6 months ago

Jade Biosciences Slides: Corporate presentation

Dec 22, 2025, 7:00 AM EST - 7 months ago

Jade Biosciences Registration statement: Registration Filing

Dec 15, 2025, 7:00 AM EST - 7 months ago

Jade Biosciences Announces $45 Million Private Placement

Nov 17, 2025, 10:30 AM EST - 8 months ago

Jade Biosciences Transcript: Jefferies London Healthcare Conference 2025

Nov 14, 2025, 7:00 AM EST - 8 months ago

Jade Biosciences Quarterly report: Q3 2025

Nov 14, 2025, 7:00 AM EST - 8 months ago

Jade Biosciences Earnings release: Q3 2025

Nov 13, 2025, 6:00 PM EST - 8 months ago

Jade Biosciences Slides: Corporate Presentation

Nov 13, 2025, 4:05 PM EST - 8 months ago

Jade Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 13, 2025, 3:00 PM EST - 8 months ago

Jade Biosciences Transcript: TD Cowen Immunology and Inflammation Summit

Nov 12, 2025, 6:00 PM EST - 8 months ago

Jade Biosciences Slides: Corporate Presentation

Nov 12, 2025, 4:00 PM EST - 8 months ago

Jade Biosciences Transcript: Stifel 2025 Healthcare Conference

Nov 8, 2025, 11:00 AM EST - 8 months ago

Jade Biosciences Presents New Data Demonstrating a Favorable Preclinical Safety Profile of JADE101 and a Translational Analysis of APRIL Mediated Biomarker Responses at the American Society of Nephrology Kidney Week 2025

Oct 17, 2025, 4:05 PM EDT - 9 months ago

Jade Biosciences Announces New Data Presentations for JADE101 at the American Society of Nephrology Kidney Week 2025

Oct 7, 2025, 8:00 AM EDT - 10 months ago

Jade Biosciences Transcript: Investor Update

Oct 7, 2025, 8:00 AM EDT - 10 months ago

Jade Biosciences Press release: Investor Update

Oct 7, 2025, 8:00 AM EDT - 10 months ago

Jade Biosciences Slides: Investor Update

Oct 7, 2025, 7:05 AM EDT - 10 months ago

Jade Biosciences Announces JADE201, a Potentially Best-in-Class Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody in Development for Autoimmune Diseases

Oct 7, 2025, 7:00 AM EDT - 10 months ago

Jade Biosciences Announces $135 Million Private Placement

Sep 16, 2025, 1:00 PM EDT - 10 months ago

Jade Biosciences Transcript: Stifel Virtual Immunology and Inflammation Forum

Sep 3, 2025, 3:20 PM EDT - 11 months ago

Jade Biosciences Transcript: Cantor Global Healthcare Conference 2025

Sep 2, 2025, 7:00 AM EDT - 11 months ago

Jade Biosciences Announces First Cohort Dosed in Phase 1 Healthy Volunteer Clinical Trial of JADE101, a Novel and Potentially Best-in-Class Anti-APRIL Monoclonal Antibody Being Evaluated for the Treatment of IgA Nephropathy

Aug 29, 2025, 12:00 PM EDT - 11 months ago

Jade Biosciences Slides: Corporate Presentation

Aug 13, 2025, 4:05 PM EDT - 11 months ago

Jade Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 13, 2025, 7:00 AM EDT - 1 year ago

Jade Biosciences Quarterly report: Q2 2025

Aug 13, 2025, 7:00 AM EDT - 1 year ago

Jade Biosciences Earnings release: Q2 2025

Jul 14, 2025, 3:00 PM EDT - 1 year ago

Jade Biosciences Transcript: H.C. Wainwright 4th Annual Kidney Virtual Conference

Jul 8, 2025, 7:00 AM EDT - 1 year ago

Jade Biosciences to Participate in Two Upcoming Investor Conferences

Jul 1, 2025, 7:00 AM EDT - 1 year ago

Jade Biosciences Appoints Brad Dahms as Chief Financial Officer

Jun 9, 2025, 8:00 AM EDT - 1 year ago

Jade Biosciences Transcript: ERA 2025 Conference

Jun 9, 2025, 8:00 AM EDT - 1 year ago

Jade Biosciences Slides: FY 2025

Jun 9, 2025, 7:00 AM EDT - 1 year ago

Jade Biosciences Presents JADE101 Preclinical Data at the 62nd European Renal Association Congress Demonstrating Potential for Best-in-Class Profile in IgA Nephropathy

Jun 8, 2025, 6:00 PM EDT - 1 year ago

Jade Biosciences Slides: Corporate Presentation

Jun 4, 2025, 12:25 PM EDT - 1 year ago

Jade Biosciences Transcript: Jefferies Healthcare Conference

Jun 2, 2025, 7:00 AM EDT - 1 year ago

Jade Biosciences to Present New Preclinical Data on JADE101 at the 62nd European Renal Association Congress

May 14, 2025, 4:05 PM EDT - 1 year ago

Jade Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 13, 2025, 6:00 PM EDT - 1 year ago

Jade Biosciences Quarterly report: Q1 2025

May 13, 2025, 6:00 PM EDT - 1 year ago

Jade Biosciences Earnings release: Q1 2025

May 13, 2025, 7:00 AM EDT - 1 year ago

Jade Biosciences to Participate in the 2025 Jefferies Global Healthcare Conference

WallStWireAds Jul. 14 at 4:18 PM

$NVCT https://seekingalpha.com/pr/20582379-streetwatch-nuvectis-pharma-eyes-9_8-billion-oral-pnh-market-with-late-stage-nxp100-backed-by $TGTX $VRTX $JBIO $CRNX

0 · Reply

focafoca99 Jul. 1 at 9:03 PM

$JBIO licensed an exclusive royalty-bearing agreement with Paragon Therapeutics, up to $22 million in milestones.

0 · Reply

focafoca99 Jun. 26 at 11:19 AM

$JBIO appointed Mark Eisner to its board of directors.

0 · Reply

stayput Jun. 24 at 5:01 PM

$JBIO Average $12.57.. sitting pretty

0 · Reply

Irish_lass Jun. 23 at 2:29 PM

$JBIO Thanks XBI

0 · Reply

Irish_lass Jun. 22 at 6:49 PM

$JBIO Swing for the fences

0 · Reply

Irish_lass Jun. 22 at 3:19 PM

$JBIO 👀

0 · Reply

outlawinvestor1 Jun. 19 at 9:59 PM

$APGE 💥🥳 $SYRE $ORKA $JBIO $CBIO https://www.reuters.com/business/healthcare-pharmaceuticals/abbvie-nears-11-billion-deal-apogee-therapeutics-ft-reports-2026-06-19/

0 · Reply

Quantumup Jun. 15 at 12:47 PM

0 · Reply

SuperGreenToday Jun. 12 at 10:17 AM

0 · Reply

focafoca99 Jun. 11 at 8:38 PM

$JBIO modified its Articles of Incorporation to waive jury trials, effective June 10, 2026.

0 · Reply

focafoca99 Jun. 4 at 9:14 PM

$JBIO offered a $15 per share public offering of 10 million shares, targeting about $140 million in net proceeds.

0 · Reply

MarketBeat Jun. 2 at 1:09 AM

https://marketbeat.com/a/8686852/ $JBIO Jade Biosciences’ JADE101 Delivers Deep IgA Cuts, Clearing Path for Kidney Trials

0 · Reply

focafoca99 Jun. 1 at 12:08 PM

$JBIO shows interim Phase 1 data with about 70% IgA reduction from JADE101 in healthy volunteers.

0 · Reply

Pagal22 May. 30 at 4:13 PM

$JBIO

0 · Reply

Pagal22 May. 30 at 4:13 PM

$JBIO

0 · Reply

Icarus81 May. 29 at 8:54 PM

$JBIO your shorts are going to burn

1 · Reply

Monkey7779192 May. 29 at 8:51 PM

$JBIO Looking at open on Monday for potential trade.

0 · Reply

Monkey7779192 May. 29 at 8:50 PM

$JBIO Looks like a good short opportunity on Monday open.

0 · Reply

Merlintrader May. 26 at 4:40 PM

$JBIO Biotech Catalyst Watch: Phase 2 IgAN Start, CRB-701 Cancer Data And Cullinan Autoimmune Updates $JBIO $CRBP $CGEM https://www.merlintrader.com/biotech-catalyst-jun2026b/

0 · Reply

outlawinvestor1 May. 16 at 10:04 AM

updated paragon family of extended life biologics. https://www.paragontherapeutics.com/ $APGE $SYRE $ORKA $JBIO $CBIO

1 · Reply

Market Cap	1.05B
Revenue (ttm)	0.00
Net Income (ttm)	-127.41M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,218,100
Avg Vol	1,102,290
Day's Range	N/A - N/A
Shares Out	49.36M
Stochastic %K	44%
Beta	1.43
Analysts	Strong Sell
Price Target	$45.89